Lo mejor del Congreso 2019 del American College of Cardiology / The best of the 2019 American College of Cardiology Congress / O melhor do Congresso do Colégio Americano de Cardiologia 2019

RESUMEN

Resumen Como todos los años, en esta oportunidad se celebró el 68º Congreso del Colegio Americano de Cardiología (ACC, por su sigla en inglés) entre los días 16 y 18 de marzo en Nueva Orleans, Luisiana. Ambientado en la ciudad del Mardi Gras y el jazz, nuevamente convocó a la cardiología mundial para promover el conocimiento a través de la presentación de múltiples actividades científicas. Contó con la presencia de más de 16.000 asistentes y se recibieron 2.300 artículos, muchos de los cuales, sin duda, modificarán la práctica clínica actual. Cabe destacar, asimismo, la presentación de la Guía de Prevención Primaria de la Enfermedad Cardiovascular, donde resalta el casi total abandono del ácido acetilsalicílico en prevención primaria debido a la falta de beneficio neto. Realizaremos un breve resumen de algunos de los principales trabajos científicos presentados - Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation - The AUGUSTUS Trial - Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients - The PARTNER 3 trial - The Safety and Efficacy of Femoral Access in STEMI The SAFARI-STEMI Trial - One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy With Clopidogrel After Drug-Eluting Stent Implantation. STOP-DAPT 2 Trial - Results of a Large-scale, App-based Study to Identify Atrial Fibrillation Using a Smartwatch The Apple Heart Study

ABSTRACT

Summary: As every year, on this occasion the 68th Congress of the American College of Cardiology was held from March 16 to 18 in New Orleans, Louisiana. Set in the city of Mardi Gras and jazz, it once again called on global cardiology to promote knowledge through the presentation of multiple scientific activities. It counted with the presence of more than 16.000 attendees and 2.300 articles were received, many of which will undoubtedly modify the current clinical practice. It is also worth mentioning the presentation of the Primary Prevention of Cardiovascular Disease Guideline, which highlights the almost total discontinuation of acetylsalicylic acid in primary prevention due to the lack of net benefit. We will make a brief summary of some of the main scientific papers presented - Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation - The AUGUSTUS Trial - Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients - The PARTNER 3 trial - The Safety and Efficacy of Femoral Access in STEMI The SAFARI-STEMI Trial - One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy With Clopidogrel After Drug-Eluting Stent Implantation. STOP-DAPT 2 Trial - Results of a Large-scale, App-based Study to Identify Atrial Fibrillation Using a Smartwatch The Apple Heart Study

RESUMO

Resumo Como todos os anos, nesta ocasião, o 68º Congresso do Colégio Americano de Cardiologia (ACC após sua sigla em inglês) foi realizado de 16 a 18 de março em Nova Orleans, Louisiana. Situado na cidade do Mardi Gras e jazz, mais uma vez convidou a cardiologia do mondo para promover o conhecimento através da apresentação de múltiplas atividades científicas. Contou com a presença de mais de 16.000 participantes e 2.300 artigos recebidos, muitos dos quais sem dúvida modificarão a prática clínica atual. Também vale ressaltar a apresentação da Diretriz para a Prevenção Primária de Doenças Cardiovasculares, que destaca o quase total abandono do ácido acetilsalicílico na prevenção primária devido à falta de benefício líquido. Faremos um breve resumo de alguns dos principais trabalhos científicos apresentados - Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation - The AUGUSTUS Trial - Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients - The PARTNER 3 trial - The Safety and Efficacy of Femoral Access in STEMI The SAFARI-STEMI Trial - One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy With Clopidogrel After Drug-Eluting Stent Implantation. STOP-DAPT 2 Trial - Results of a Large-scale, App-based Study to Identify Atrial Fibrillation Using a Smartwatch The Apple Heart Study